Expedition Therapeutics Raises $115 Million as COPD Phase 2 Starts

Company: Expedition Therapeutics · Event Type: Series B Financing + Clinical Milestone · Amount: $115 Million · Lead Investor: General Atlantic · Asset: EXPD-101 (Oral DPP1 Inhibitor) · Indication: COPD Summary Expedition Therapeutics closed an oversubscribed $115 million Series B led by General Atlantic, with…